Foghorn® Therapeutics Inc. (Nasdaq: FHTX) has announced Chief Financial Officer Allan Reine’s departure to pursue a new opportunity. The company has initiated a formal search for a successor, with Dr. Reine’s last day as a full-time Foghorn employee set for January 16, 2024.
Foghorn Therapeutics specializes in identifying and developing medications that target specific genetic dependencies within the chromatin regulatory system.
Adrian Gottschalk, Foghorn’s President and CEO, expressed gratitude for Allan’s leadership and dedication during his tenure.
Have you read?
23 of the Biggest Wars in Human History.
Movies that Catapulted Hollywood Icons.
Countries with the Most American Military Bases.
Countries With The Most Main Battle Tanks Today.
Silver Screen Disasters: Epic Failures in Hollywood.
Add CEOWORLD magazine to your Google News feed.
Follow CEOWORLD magazine headlines on: Google News, LinkedIn, Twitter, and Facebook.
Copyright 2024 The CEOWORLD magazine. All rights reserved. This material (and any extract from it) must not be copied, redistributed or placed on any website, without CEOWORLD magazine' prior written consent. For media queries, please contact: info@ceoworld.biz
